According to the Biden Administration, the previous administration created loopholes that allowed the marketing of misleading insurance products that can discriminate based on pre-existing conditions.

"Unions are on a playing field that has never been more favorable for them, at least not in the last decade," says one legal expert.

Patients with early Alzheimer's disease who took lecanemab in a major clinical trial declined an average of five months slower than other subjects over an 18-month period.